Infographic | March 18, 2024

Challenges And Opportunities When Manufacturing High-Concentration Biotech Drugs

Source: Cytiva
GettyImages-1218359147 Subcutaneous injection

Monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and recombinant proteins are growing increasingly important as therapeutics for a variety of treatments including cancer, diabetes, and autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS).

As the applications continue to expand for these therapeutics, producing these drugs in a format that can be administered to patients subcutaneously presents significant advantages compared to IV infusion.

Explore opportunities to enhance your platform for high-concentration/subcutaneous drug production.

access the Infographic!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Biosimilar Development